To test this hypothesis, we were able to stain PBMCs from three of the AML patients for Blimp-1 protein before and after treatment and observed strong upregulation in B, T, and NK cells after HMA/venetoclax therapy (Supplementary Figure S1G,H). Here, PRDM1 is linked to acute myeloid leukemia.